Aurora SpineASAPF -4.29%39 Debt-to-EBITDA is 9.41 as of Mar. 2026. GuruFocus rates ASAPF with a GF Score™ of 39/100 and a GF Value™ of $0.21 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Aurora Spine ranks worse than 85.04% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Aurora Spine's Debt-to-EBITDA or its related term are showing as below:
ASAPF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.18 Med: -1.64 Max: 20.43
Current: 5.51
During the past 13 years, the highest Debt-to-EBITDA Ratio of Aurora Spine was 20.43. The lowest was -8.18. And the median was -1.64.
ASAPF's Debt-to-EBITDA is ranked worse than 85.04% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.555
vs ASAPF: 5.51
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Aurora Spine Debt-to-EBITDA Related Terms
Aurora Spine Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Aurora Spine's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Aurora Spine's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurora Spine Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aurora Spine's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aurora Spine's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Aurora Spine (ASAPF) has a Debt-to-EBITDA of 9.41 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Aurora Spine. According to the industry distribution chart, Aurora Spine ranks #398 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 85%.
Is Aurora Spine's Debt-to-EBITDA too high?
Aurora Spine's current Debt-to-EBITDA is 9.41. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.56. Aurora Spine's value of 9.41 is 505.1% above this industry median. Based on the distribution chart, Aurora Spine ranks #398 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Aurora Spine has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aurora Spine's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aurora Spine ranks #398 out of 468 companies for Debt-to-EBITDA. This places Aurora Spine in the lower half of its industry. The industry median Debt-to-EBITDA is 1.56. Aurora Spine's value of 9.41 is 505.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.56, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurora Spine's current Debt-to-EBITDA of 9.41 is 505.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Aurora Spine. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurora Spine's current Debt-to-EBITDA is 9.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurora Spine stock overvalued right now?
Based on GuruFocus' analysis, Aurora Spine (ASAPF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.21, compared to a current price of $0.17 — trading 20.2% below its estimated fair value. The current Debt-to-EBITDA is 9.41 and 505.1% above the Medical Devices & Instruments industry median of 1.56. Aurora Spine's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Aurora Spine (ASAPF), the current Debt-to-EBITDA is 9.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurora Spine (ASAPF) Overvalued in 2026?
Based on GuruFocus' analysis, Aurora Spine stock appears to be undervalued.
The current stock price of $0.17 is trading 20.2% below its estimated GF Value™ of $0.21.
GuruFocus considers Aurora Spine to be Possible Value Trap.
Key valuation signals for ASAPF:
Debt-to-EBITDA: 9.41
GF Value™: $0.21 vs. price of $0.17 (20.2% below fair value)
Industry Position: 505.1% above the Medical Devices & Instruments median (#398 of 468)
No single metric tells the full story. See the ASAPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurora Spine Corp is engaged in the development, manufacture, and sale of minimally invasive, interspinous fusion systems and devices. These 510K and patent protected medical devices improve patient outcomes in the area of spine and sacroiliac joint surgical procedures. The company is focused on bringing new solutions to the spinal implant market through a series of minimally invasive, regenerative spinal implant technologies.
39GF Score
Get the complete analysis for ASAPF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASAPF has been successfully added to your 
